Having implanted more than 13,000 Kamra corneal inlays (AcuFocus) in the past 5 years, my experience with this technology accounts for about 80% of all international cases. Given these facts, it is fair to say that I have helped to refine not only the technique for implantation but also the technology itself. With such a vested interest in the Kamra corneal inlay, I was excited to hear of its recent approval by the FDA. In my opinion, the Kamra affords patients improvements in near and intermediate visual acuity, better contrast sensitivity than an accommodating or diffractive multifocal IOL,1 and minimal compromise to distance vision.
METHODS OF IMPLANTATION
I began using the Kamra during my time as the executive medical director at Shinagawa LASIK Center in Tokyo, and I continue to use the device now that I am in private practice at the Minoru Tomita Eye Clinic Ginza. In my early experience, the inlay was implanted using a technique that the company called combined LASIK-Kamra (CLK), whereby the inlay was implanted simultaneously with LASIK under a 200-µm lamellar flap. CLK was subsequently abandoned, as operating under a thick flap proved to have obvious disadvantages for patients (induction of dry eye, slow visual recovery) and surgeons (difficulty centering the inlay for implantation, extensive postoperative management). Furthermore, AcuFocus global registry data showed that the incidence of a wound-healing response was 17% with the CLK technique (data on file with AcuFocus), and my explantation rate in nearly 4,000 cases was approximately 5%. I found that the reasons for removal included patients' dissatisfaction with their vision and/or failure to adapt to their vision with the inlay.
Today, the inlay is implanted into a lamellar pocket at or deeper than 200 µm, and, in 90% of cases, the device is combined with LASIK using a dual-interface technique. In this approach, the excimer laser correction is performed under a thin flap, and the inlay is implanted at least 100 µm below the LASIK interface, inside a corneal pocket. The pocket is created with a femtosecond laser using a spot/line separation of 6 X 6 (or the equivalent) because my fellow investigators and I have concluded that this produces smoother beds and better postoperative outcomes than other spot/line separations.
I have implanted about 9,000 corneal inlays with the corneal pocket technique, and my overall explantation rate is somewhere between 1% and 2% within 3 years of implantation (see Retrospective Analysis of Inlay Removal and FDA Clinical Trial Data on Reasons for Explantation). In a recent study of 223 eyes undergoing the corneal pocket procedure, the mean near UCVA improved by 4 lines, from J8 preoperatively to J2 at 6 months postoperatively (P<.001), and patients' spectacle dependence and satisfaction with spectacle-free reading improved significantly.2
The advantages a dual-interface technique include the ability to fine-tune patients' refractions and to capitalize on the advantages of thin-flap LASIK and deep-pocket corneal inlay implantation. With that said, some patients (4%) still experience an aggressive wound-healing response characterized by stromal thickening over the inlay, central flattening, the development of haze over the inlay annulus, and a hyperopic shift after inlay implantation with a corneal pocket technique. In the vast majority of these patients, however, the wound-healing response can be resolved with steroid therapy.3 Inlay explantation should be considered if the eye either does not respond to steroids or rebounds after treatment.
As previously mentioned, my removal rate with the Kamra corneal inlay decreased from 5% with the CLK technique to between 1% and 2% with pocket implantation. This closely reflects data from the AcuFocus global registry (6% with CLK and 1.2% with pocket implantation; Figure 1). These removal rates are comparable to the reversal rate of monovision4,5 and approach the rate of IOL exchange.6
For this reason, and because of the advantages of pocket implantation outlined earlier, the AcuFocus Global Medical Advisory Board now recommends that the Kamra always be implanted in a corneal pocket.
Although a small percentage of patients experience a hyperopic shift postoperatively, in general, presbyopes who are motivated to achieve spectacle independence do well with the Kamra corneal inlay implanted in their nondominant eye. Compared with the other available corneal inlays, I believe that the Kamra is the best option for my patients. This is mainly because the Kamra is the only technology that can maintain a distance visual acuity of 20/20 and provide patients with near and intermediate visual acuity in the range of J1 to J2 (personal experience). Additionally, surgical complications are rare and have decreased with advances in implantation technique.7,8 n
1. Pepose J. Comparison of depth of focus and mesopic contrast sensitivity in small-aperture inlay, accommodating IOL, and multifocal IOL patients. Poster presented at: The 2014 ASCRS/ASOA Symposium & Congress; April 25-29, 2014; Boston, MA.
2. Tomita M, Kanamori T, Waring GO IV, et al. Small-apeture corneal inlay implantation to treat presbyopia after laser in situ keratomileusis. J Cataract Refract Surg. 2013;39(6):898-905.
3. Dexl AK, Jell G, Strohmaier C, et al. Long-term outcomes after monocular corneal inlay implantation for the surgical compensation of presbyopia. J Cataract Refract Surg. 2015;41:566-575.
4. Reilly CD, Lee WB, Alvarenga L, et al. Surgical monovision and monovision reversal in LASIK. Cornea. 2006;25(2):136-138.
5. Braun EH, Lee J, Steinert RF. Monovision in LASIK. Ophthalmology. 2008;115(7):1196-1202.
6. Marketscope 2012: IOL report.
7. Tomita M, Waring GO IV. One-year results of simultaneous laser in situ keratomileusis and small-apeture corneal inlay implantation for hyperopic presbyopia: Comparison by age. J Cataract Refract Surg. 2015;41(1):152-161.
8. Tomita M, Kanamori T, Waring GO IV, et al. Simultaneous corneal inlay implantation and laser in situ keratomileusis for presbyopia in patients with hyperopia, myopia, or emmetropia: Six-month results. J Cataract Refract Surg. 2012;38(3):495-506.
Minoru Tomita, MD, PhD
• CEO, Eye Can Medical Group
• Medical Director, Minoru Tomita Eye Clinic Ginza, Tokyo, Japan
• Adjunct Clinical Professor of Ophthalmology, Wenzo University, Wenzhou, Zhejiang, Japan
• Financial disclosure: Global Medical Advisory Board (AcuFocus)